Concert Pharmaceuticals completes enrollment in second open label trial of CTP-543 in alopecia areata

Concert Pharmaceuticals announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in patients with alopecia areata.